Posters

      Product experience and risk perceptions in Platform 1 users: a cross-sectional survey in Japan

      Langer, P.; Sponsiello-Wang, Z.; Prieto, L.; Dobrynina, M.; Skiada, D.; Camille, N.; Weitkunat, R.; Lüdicke, F.
      Conference date
      Jun 15, 2018
      Conference name
      Global Forum on Nicotine (GFN) 2018
      Link to more information
      Link to more information
      Link to more information
      Topic
      Summary

      To learn more on the research and methods behind this poster, you’ll find a complementary brochure here - or view the poster and brochure together here.

      Related Publications

      Estimated public health gains from smokers in Germany switching to reduced-risk alternatives: Results from population health impact modelling by socioeconomic group

      Post-Market Studies and Surveillance Study

      Estimated public health gains from German smokers switching to reduced-risk alternatives: Results from population health impact modelling

      Post-Market Studies and Surveillance Study

      <p>Trends in prevalence and patterns of use of a heated tobacco product (<i>IQOS</i>™) in Japan: A three-year repeated cross-sectional study [version 1; peer review: 2 approved with reservations]</p>

      Post-Market Studies and Surveillance Study

      Prevalence and patterns of tobacco and/or nicotine product use in Japan (2017) after the launch of a heated tobacco product (IQOS®): a cross-sectional study

      Post-Market Studies and Surveillance Study

      Trends in hospitalization due to COPD and IHD before and after the introduction of HTPs in Japan

      Post-Market Studies and Surveillance Study

      Insights on the impact of the introduction of heated tobacco products in Japan on sales of cigarettes and the smoking prevalence

      Post-Market Studies and Surveillance Study

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.